Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 20 |
| List of Tables | 18 | 3 |
| List of Figures | 21 | 1 |
| Introduction | 22 | 1 |
| Global Markets Direct Report Coverage | 22 | 1 |
| Cystic Fibrosis Overview | 23 | 1 |
| Therapeutics Development | 24 | 2 |
| Pipeline Products for Cystic Fibrosis Overview | 24 | 1 |
| Pipeline Products for Cystic Fibrosis Comparative Analysis | 25 | 1 |
| Cystic Fibrosis Therapeutics under Development by Companies | 26 | 6 |
| Cystic Fibrosis Therapeutics under Investigation by Universities/Institutes | 32 | 1 |
| Cystic Fibrosis Pipeline Products Glance | 33 | 4 |
| Late Stage Products | 33 | 1 |
| Clinical Stage Products | 34 | 1 |
| Early Stage Products | 35 | 1 |
| Unknown Stage Products | 36 | 1 |
| Cystic Fibrosis Products under Development by Companies | 37 | 8 |
| Cystic Fibrosis Products under Investigation by Universities/Institutes | 45 | 1 |
| Cystic Fibrosis Companies Involved in Therapeutics Development | 46 | 74 |
| Actelion Ltd | 46 | 1 |
| Alaxia SAS | 47 | 1 |
| AlgiPharma AS | 48 | 1 |
| AmpliPhi Biosciences Corporation | 49 | 1 |
| Arch Biopartners, Inc. | 50 | 1 |
| Arcturus Therapeutics, Inc. | 51 | 1 |
| Aridis Pharmaceuticals LLC | 52 | 1 |
| AstraZeneca Plc | 53 | 1 |
| Bayer AG | 54 | 1 |
| BioAegis Therapeutics, Inc. | 55 | 1 |
| Boehringer Ingelheim GmbH | 56 | 1 |
| Calista Therapeutics, Inc. | 57 | 1 |
| Catabasis Pharmaceuticals, Inc. | 58 | 1 |
| Celtaxsys, Inc. | 59 | 1 |
| Chrysalis Pharma SAS | 60 | 1 |
| Cilian AG | 61 | 1 |
| Concert Pharmaceuticals, Inc. | 62 | 1 |
| CRISPR Therapeutics | 63 | 1 |
| CSA Biotechnologies LLC | 64 | 1 |
| Cyclacel Pharmaceuticals, Inc. | 65 | 1 |
| DiscoveryBiomed, Inc. | 66 | 1 |
| Editas Medicine, Inc. | 67 | 1 |
| Eloxx Pharmaceuticals, Ltd. | 68 | 1 |
| Errant Gene Therapeutics, LLC | 69 | 1 |
| Eumedica SA | 70 | 1 |
| Galapagos NV | 71 | 1 |
| Gilead Sciences, Inc. | 72 | 1 |
| GlaxoSmithKline Plc | 73 | 1 |
| Grupo Praxis Pharmaceutical SA | 74 | 1 |
| Horizon Pharma Plc | 75 | 1 |
| ID Pharma Co., Ltd. | 76 | 1 |
| Immun System I.M.S. AB | 77 | 1 |
| Insmed Incorporated | 78 | 1 |
| Invion Limited | 79 | 1 |
| JHL Biotech, Inc. | 80 | 1 |
| Kamada Ltd. | 81 | 1 |
| Kyorin Pharmaceutical Co., Ltd. | 82 | 1 |
| La Jolla Pharmaceutical Company | 83 | 1 |
| Lakewood-Amedex Inc | 84 | 1 |
| Lamellar Biomedical Ltd | 85 | 1 |
| Laurent Pharmaceuticals Inc. | 86 | 1 |
| Mast Therapeutics, Inc. | 87 | 1 |
| Merck &Co., Inc. | 88 | 1 |
| Microbion Corporation | 89 | 1 |
| Mucokinetica Ltd. | 90 | 1 |
| Nivalis Therapeutics, Inc. | 91 | 1 |
| Novabiotics Limited | 92 | 1 |
| Novartis AG | 93 | 1 |
| OSE Immunotherapeutics | 94 | 1 |
| Paranta Biosciences Limited | 95 | 1 |
| Parion Sciences, Inc. | 96 | 1 |
| Pfizer Inc. | 97 | 1 |
| Pharmaxis Limited | 98 | 1 |
| PhaseBio Pharmaceuticals, Inc. | 99 | 1 |
| Polyphor Ltd. | 100 | 1 |
| Progenra, Inc. | 101 | 1 |
| ProMetic Life Sciences Inc. | 102 | 1 |
| ProQR Therapeutics N.V. | 103 | 1 |
| Protalix BioTherapeutics, Inc. | 104 | 1 |
| Proteostasis Therapeutics, Inc. | 105 | 1 |
| PTC Therapeutics, Inc. | 106 | 1 |
| Pulmatrix, Inc. | 107 | 1 |
| Raptor Pharmaceutical Corp. | 108 | 1 |
| ReveraGen BioPharma, Inc. | 109 | 1 |
| Savara Inc. | 110 | 1 |
| Shionogi &Co., Ltd. | 111 | 1 |
| Shire Plc | 112 | 1 |
| Synovo GmbH | 113 | 1 |
| TGV-Laboratories | 114 | 1 |
| The International Biotechnology Center (IBC) Generium | 115 | 1 |
| Verona Pharma Plc | 116 | 1 |
| Vertex Pharmaceuticals Incorporated | 117 | 1 |
| Xenetic Biosciences (UK) Limited | 118 | 1 |
| Zambon Company S.p.A. | 119 | 1 |
| Cystic Fibrosis Therapeutics Assessment | 120 | 14 |
| Assessment by Monotherapy Products | 120 | 1 |
| Assessment by Combination Products | 121 | 1 |
| Assessment by Target | 122 | 4 |
| Assessment by Mechanism of Action | 126 | 4 |
| Assessment by Route of Administration | 130 | 2 |
| Assessment by Molecule Type | 132 | 2 |
| Drug Profiles | 134 | 230 |
| (ammonium chloride + citric acid + sodium citrate) Drug Profile | 134 | 1 |
| (fosfomycin + tobramycin) Drug Profile | 135 | 1 |
| (ivacaftor + tezacaftor) Drug Profile | 136 | 4 |
| ABPA-01 Drug Profile | 140 | 3 |
| acebilustat Drug Profile | 143 | 3 |
| Aerucin Drug Profile | 146 | 1 |
| alpha-1 proteinase inhibitor (human) second generation Drug Profile | 147 | 3 |
| ALX-009 Drug Profile | 150 | 1 |
| amikacin sulfate Drug Profile | 151 | 9 |
| amlexanox Drug Profile | 160 | 1 |
| Anti-Pseudomonas IgY Drug Profile | 161 | 1 |
| Antimicrobial Drug for Cystic Fibrosis Drug Profile | 162 | 1 |
| AT-010 Drug Profile | 163 | 1 |
| ataluren Drug Profile | 164 | 9 |
| AZD-5634 Drug Profile | 173 | 1 |
| BI-443651 Drug Profile | 174 | 1 |
| Biologics for Cystic Fibrosis Lung Infections Drug Profile | 175 | 1 |
| Biologics for Multi Drug Resistant Bacterial Infections, Dermatology and Cystic Fibrosis Drug Profile | 176 | 1 |
| brevenal Drug Profile | 177 | 1 |
| Calcaftor Drug Profile | 178 | 1 |
| CAT-4001 Drug Profile | 179 | 1 |
| cavosonstat Drug Profile | 180 | 2 |
| CSA-13 Drug Profile | 182 | 1 |
| CSY-0073 Drug Profile | 183 | 1 |
| CTP-656 Drug Profile | 184 | 3 |
| cysteamine hydrochloride Drug Profile | 187 | 2 |
| doripenem Drug Profile | 189 | 2 |
| dornase alfa biosimilar Drug Profile | 191 | 1 |
| dornase alfa biosimilar Drug Profile | 192 | 1 |
| DP-01 Drug Profile | 193 | 1 |
| Drugs for Cystic Fibrosis Drug Profile | 194 | 1 |
| edetate disodium + sodium nitrite Drug Profile | 195 | 2 |
| ELX-02 Drug Profile | 197 | 1 |
| FDL-169 Drug Profile | 198 | 1 |
| fenretinide Drug Profile | 199 | 1 |
| Gene Therapy to Activate CFTR for Cystic Fibrosis Drug Profile | 200 | 1 |
| Gene Therapy to Activate CFTR for Cystic Fibrosis Drug Profile | 201 | 1 |
| Gene Therapy to Activate CFTR for Cystic Fibrosis Drug Profile | 202 | 1 |
| Gene Therapy to Activate CFTR for Cystic Fibrosis Drug Profile | 203 | 1 |
| Gene Therapy to Activate CFTR Gene for Cystic Fibrosis Drug Profile | 204 | 1 |
| GLPG-1837 Drug Profile | 205 | 2 |
| GLPG-1837 + GLPG-2222 + GLPG-2665 Drug Profile | 207 | 1 |
| GLPG-2222 Drug Profile | 208 | 1 |
| GLPG-2451 Drug Profile | 209 | 1 |
| GLPG-2665 Drug Profile | 210 | 1 |
| GLPG-2737 Drug Profile | 211 | 1 |
| GLPG-2851 Drug Profile | 212 | 1 |
| glycerol phenylbutyrate Drug Profile | 213 | 5 |
| GS-5745 Drug Profile | 218 | 2 |
| GSK-2225745 Drug Profile | 220 | 1 |
| itraconazole Drug Profile | 221 | 2 |
| JBT-101 Drug Profile | 223 | 4 |
| kenpaullone Drug Profile | 227 | 1 |
| KRP-109 Drug Profile | 228 | 1 |
| levofloxacin Drug Profile | 229 | 4 |
| LJPC-30Sa Drug Profile | 233 | 1 |
| LJPC-30Sb Drug Profile | 234 | 1 |
| LMS-611 Drug Profile | 235 | 1 |
| LUNAR-CF Drug Profile | 236 | 1 |
| mannitol Drug Profile | 237 | 5 |
| MG-277 Drug Profile | 242 | 1 |
| miglustat Drug Profile | 243 | 2 |
| MKA-104 Drug Profile | 245 | 1 |
| Mul-1867 Drug Profile | 246 | 1 |
| nadolol Drug Profile | 247 | 4 |
| nitric oxide Drug Profile | 251 | 2 |
| nitric oxide Drug Profile | 253 | 1 |
| Nu-3 Drug Profile | 254 | 2 |
| NVPQBE-170 Drug Profile | 256 | 1 |
| Oligomer G for Cystic Fibrosis Drug Profile | 257 | 2 |
| ORP-100 Drug Profile | 259 | 1 |
| PAC-IC Drug Profile | 260 | 1 |
| Panaecin Drug Profile | 261 | 1 |
| PB-1046 Drug Profile | 262 | 2 |
| PB-1120 Drug Profile | 264 | 1 |
| PBI-4050 Drug Profile | 265 | 5 |
| Peptides for Cystic Fibrosis and Pseudomonas Infections Drug Profile | 270 | 1 |
| POL-6014 Drug Profile | 271 | 2 |
| POL-7001 Drug Profile | 273 | 1 |
| PRX-110 Drug Profile | 274 | 1 |
| PTI-130 Drug Profile | 275 | 1 |
| PTI-428 Drug Profile | 276 | 2 |
| PTIC-1811 Drug Profile | 278 | 1 |
| PTINC-733 Drug Profile | 279 | 1 |
| PTIP-271 Drug Profile | 280 | 1 |
| PulmoXen Drug Profile | 281 | 1 |
| PXS-4728A Drug Profile | 282 | 1 |
| QR-010 Drug Profile | 283 | 2 |
| QRX-021 Drug Profile | 285 | 1 |
| QRX-4 Drug Profile | 286 | 1 |
| Recombinant Acid Ceramidase Replacement for Farber Disease and Cystic Fibrosis Drug Profile | 287 | 1 |
| Recombinant Enzyme to Target DNA for Cystic Fibrosis Drug Profile | 288 | 1 |
| Recombinant Plasma Gelsolin Replacement for Cystic Fibrosis and Bronchiectasis Drug Profile | 289 | 1 |
| Recombinant Protein for Infectious Diseases and Respiratory Disorders Drug Profile | 290 | 1 |
| riociguat Drug Profile | 291 | 6 |
| RPL-554 Drug Profile | 297 | 8 |
| RvE-1 Drug Profile | 305 | 1 |
| S-1226 Drug Profile | 306 | 2 |
| S-1229 Drug Profile | 308 | 1 |
| seliciclib Drug Profile | 309 | 2 |
| SHP-637 Drug Profile | 311 | 1 |
| Small Molecule for Cystic Fibrosis Drug Profile | 312 | 1 |
| Small Molecule for Pneumonia, COPD, Cystic Fibrosis and Pulmonary Tuberculosis Drug Profile | 313 | 1 |
| Small Molecule to Activate CFTR for Cystic Fibrosis Drug Profile | 314 | 1 |
| Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease Drug Profile | 315 | 1 |
| Small Molecule to Inhibit HDAC for Cystic Fibrosis and COPD Drug Profile | 316 | 1 |
| Small Molecules for Bacterial Infections Drug Profile | 317 | 1 |
| Small Molecules for Bacterial Infections, Oncology and Cystic Fibrosis Drug Profile | 318 | 1 |
| Small Molecules for Cystic Fibrosis Drug Profile | 319 | 1 |
| Small Molecules for Cystic Fibrosis Drug Profile | 320 | 1 |
| Small Molecules for Cystic Fibrosis Drug Profile | 321 | 1 |
| Small Molecules for Pseudomonas Infections and Cystic Fibrosis Drug Profile | 322 | 1 |
| Small Molecules to Activate CFTR for Cystic Fibrosis Drug Profile | 323 | 1 |
| Small Molecules to Activate CFTR Protein for Cystic Fibrosis Drug Profile | 324 | 1 |
| Small Molecules to Agonize Histamine H4 Receptor for Cystic Fibrosis and Idiopathic Pulmonary Fibrosis Drug Profile | 325 | 1 |
| Small Molecules to Block SCNN1 for Cystic Fibrosis Drug Profile | 326 | 1 |
| Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis Drug Profile | 327 | 1 |
| Small Molecules to Inhibit SSAO and MPO for Respiratory Disorders Drug Profile | 328 | 1 |
| sodium nitrite Drug Profile | 329 | 3 |
| solithromycin Drug Profile | 332 | 12 |
| SP-14 Drug Profile | 344 | 1 |
| SP-9 Drug Profile | 345 | 1 |
| SPX-101 Drug Profile | 346 | 1 |
| Stem Cell Therapy for Cystic Fibrosis Drug Profile | 347 | 1 |
| SYGN-113 Drug Profile | 348 | 1 |
| SYGN-303 Drug Profile | 349 | 1 |
| TA-270 Drug Profile | 350 | 1 |
| temocillin Drug Profile | 351 | 1 |
| trimethylangelicin Drug Profile | 352 | 1 |
| tritoqualine Drug Profile | 353 | 1 |
| vamorolone Drug Profile | 354 | 2 |
| vancomycin hydrochloride Drug Profile | 356 | 2 |
| VX-152 Drug Profile | 358 | 1 |
| VX-371 Drug Profile | 359 | 2 |
| VX-440 Drug Profile | 361 | 1 |
| VX-551 Drug Profile | 362 | 1 |
| ZP-046 Drug Profile | 363 | 1 |
| Cystic Fibrosis Dormant Projects | 364 | 11 |
| Cystic Fibrosis Discontinued Products | 375 | 1 |
| Cystic Fibrosis Product Development Milestones | 376 | 12 |
| Featured News &Press Releases | 376 | 1 |
| Sep 12, 2016: Corbus Pharmaceuticals Announces Last Subject Enrolled in Phase 2 Study of Resunab for the Treatment of Cystic Fibrosis | 376 | 1 |
| Sep 07, 2016: Raptor Pharmaceutical Presents Results from Meta-Analysis Demonstrating Efficacy of QUINSAIR Comparable to Other Approved, Inhaled Antibiotics in Cystic Fibrosis Patients | 376 | 1 |
| Aug 24, 2016: Raptor Pharmaceutical to Present Data on QUINSAIR and Other Inhaled Antibiotics at the ERS International Congress | 377 | 1 |
| Aug 18, 2016: Spyryx Biosciences Expands Executive Team, Appoints Pulmonary Industry Leader, Alistair Wheeler, MD, MFPM as Chief Medical Officer | 377 | 1 |
| Aug 17, 2016: Pulmatrix Receives Orphan Drug Designation from the FDA for Inhaled Drug to Treat Pulmonary Fungal Infections in Cystic Fibrosis Patients | 378 | 1 |
| Aug 15, 2016: Vertex Provides Update on Ongoing Phase 3 Program for VX-661 in Combination with Ivacaftor for the Treatment of Cystic Fibrosis | 379 | 1 |
| Aug 10, 2016: Arch Biopartners Engages Catalent to Begin Manufacturing Process for AB569 | 380 | 1 |
| Jul 26, 2016: Laurent Pharmaceuticals Receives US$ 3M Development Award From Cystic Fibrosis Foundation Therapeutics | 380 | 1 |